Tirzepatide’s dual-agonist mechanism, in plain English.

The tirzepatide mechanism of action hits two gut hormones at once. The first is GLP-1. It had been the star of obesity pharmacology for two decades. The second is GIP. It had been dismissed as a sidekick. Then tirzepatide worked in the clinic. The field had to think again.

For most of the GLP-1 era, GIP was the “forgotten incretin.” That era runs roughly 2005 to 2020. Both hormones were discovered around the same time. Both originate from gut endocrine cells. GLP-1 received the bulk of drug-development attention. It produced clear glucose-lowering and body-weight-reduction signals in clinical studies. GIP was largely dismissed. Research subjects with type 2 diabetes appeared to develop “GIP resistance” in hyperglycemic states.

Tirzepatide changed that. Eli Lilly’s LY3298176 program had one design question. Would reactivating GIP alongside GLP-1 add meaningful benefit? The SURPASS and SURMOUNT trials answered it definitively. This article walks through what each receptor does. It covers how the molecule was engineered, and why dual targeting outperforms GLP-1 alone.

The GLP-1 arm: the familiar half

GLP-1 (glucagon-like peptide-1) is a well-characterized incretin. L-cells in the lower small intestine and colon release it after a meal. It binds the GLP-1 receptor. Studies have documented four principal downstream effects.

• Glucose-dependent insulin release. Pancreatic β-cells increase insulin secretion in proportion to circulating glucose. When glucose is low, the trigger does not fire — which is why GLP-1 receptor agonists have not been associated with hypoglycemia in studies of non-insulin-dependent subjects.
• Glucagon suppression. At postprandial levels, GLP-1 attenuates pancreatic α-cell glucagon secretion, reducing hepatic glucose output.
• Slowed gastric emptying. Preclinical and clinical studies have reported reduced gastric motility, prolonging nutrient transit and extending postprandial satiety signals.
• Central satiety signaling. GLP-1 receptors in the hindbrain and hypothalamus mediate appetite-suppression effects observed in animal models and human clinical trials.

Selective GLP-1 agonists (liraglutide, semaglutide) have produced roughly 6–15% weight reduction in clinical trials depending on dose — a ceiling the field had been working against prior to dual-agonist development.

The GIP arm: the underestimated half

GIP (glucose-dependent insulinotropic polypeptide, originally called gastric inhibitory polypeptide) is the other incretin. It is released from K-cells in the upper small intestine postprandially. Its receptor (GIPR) is expressed in pancreatic β-cells, adipose tissue, bone, and select brain regions.

A key mechanistic point established in the literature: GIP's receptor distribution only partially overlaps GLP-1's. The pancreatic distribution is shared. The adipose-tissue and brain distributions are largely distinct. Preclinical studies have attributed additive — rather than redundant — effects to simultaneous activation of both receptors, essentially engaging two partly-different downstream machines.

Documented effects of GIPR activation in published research:

• Augmented postprandial insulin secretion. GIPR and GLP-1R both drive glucose-dependent insulin release from pancreatic β-cells. Studies have reported that co-activation produces greater insulin output than either receptor alone at equivalent glycemic levels.
• Adipose lipid handling. GIP receptors in adipose tissue have been shown to modulate postprandial lipid storage and release. Clinical trial data have associated dual agonism with improved insulin sensitivity in adipose tissue beyond what weight reduction alone would predict.
• Additional central satiety signaling. GIPR activation has been reported to engage hypothalamic appetite circuits not fully reached by GLP-1R — including neuropeptide Y and POMC pathways — in preclinical models.
• Possible attenuation of GLP-1-driven nausea. Preclinical work has suggested GIPR co-agonism may reduce GLP-1-mediated nausea via central pathways. This remains under active investigation.

The clinical validation of GIPR co-agonism came from the SURPASS-2 trial. Tirzepatide outperformed semaglutide 1 mg on both glycemic control and weight reduction in study participants with type 2 diabetes — a head-to-head that effectively settled the "forgotten incretin" debate in the field.

How Eli Lilly engineered LY3298176

The compound now sold as Mounjaro and Zepbound was called LY3298176 in early development. Eli Lilly had been working on incretin co-agonist candidates for over a decade. The hypothesis was specific: hit both GIPR and GLP-1R, see if the combination beats either alone.

Three design choices distinguished LY3298176 from earlier dual-agonist attempts.

• The potency balance leans toward GIP. Tirzepatide binds GIPR roughly 5-fold tighter than GLP-1R — a deliberate design choice to emphasize the GIP arm's contribution to weight reduction beyond glucose control.
• Extended half-life via fatty-acid tail. Like semaglutide, tirzepatide carries a long C20 fatty-acid chain that reversibly binds albumin in plasma, extending the circulatory half-life to approximately one week and enabling once-weekly subcutaneous dosing in clinical use.
• 39-amino-acid linear peptide scaffold. The backbone builds on a GLP-1 / glucagon family template, with sequence modifications engineered to maintain dual-receptor binding and resist endogenous proteolytic degradation.

Phase II and III trials between 2018 and 2022 progressively built up the clinical profile. FDA approved tirzepatide as Mounjaro (for type 2 diabetes) in May 2022, and as Zepbound (for obesity) in November 2023.

Why does hitting two receptors beat one?

The SURPASS-2 head-to-head trial provides the most direct comparative evidence published to date. Frías and colleagues compared tirzepatide (5, 10, and 15 mg) directly against semaglutide 1 mg in 1,879 study participants with type 2 diabetes. Every tirzepatide dose outperformed semaglutide on both glycemic control and weight reduction. The 15 mg arm produced approximately 0.4 percentage points more HbA1c reduction and nearly twice the body-weight reduction (11.2 kg vs 5.7 kg).

Three mechanisms have been proposed to explain the dual-agonist advantage.

Augmented pancreatic insulin secretion. Both receptors drive glucose-dependent insulin secretion through overlapping but non-identical intracellular pathways. Studies have reported that combined receptor activation produces greater insulin output than either receptor alone at matched glucose levels — accounting for much of the observed differential HbA1c reduction.

Broader central satiety signaling. GLP-1R and GIPR engage partly distinct hypothalamic circuits. GLP-1R activity is concentrated in hindbrain and POMC neuron pathways, while GIPR adds NPY-related circuits and additional hypothalamic targets. Co-activation of both receptor populations has been associated with larger appetite-suppression signals than single-receptor maximal stimulation in preclinical models.

Adipose lipid handling. GIPR expression in adipocytes modulates postprandial lipid storage and release via mechanisms that GLP-1R does not fully engage. Clinical trial data have shown that study participants receiving tirzepatide exhibited improvements in lipid profiles and insulin sensitivity exceeding what body-weight reduction alone would predict — a finding consistent with the distinct adipose GIPR component.

What about the GI side effects?

When tirzepatide first entered trials, one open question was whether adding GIPR agonism would worsen the GI tolerability profile seen with GLP-1 agonists. SURMOUNT and SURPASS data addressed this directly. At the highest doses studied, nausea was reported in roughly 33% of trial participants, diarrhea in 22%, and vomiting in 12%. Those rates are broadly similar to high-dose semaglutide — suggesting GIPR co-agonism did not materially worsen GI tolerability.

Some preclinical data has suggested GIPR co-agonism may actually attenuate GLP-1-driven nausea through central pathways, though this hypothesis remains under investigation. In the SURMOUNT and SURPASS clinical programs, GI adverse events were generally managed through gradual dose escalation protocols, consistent with the approach used for the established GLP-1 agonist class.

What's next: the triple-agonist generation

Tirzepatide's success set the template for retatrutide. The logic was simple: if hitting two receptors beats hitting one, would hitting three beat hitting two?

Retatrutide adds a third receptor target: glucagon. That arm is not redundant with GIP or GLP-1. Glucagon receptor activation has been reported to boost basal energy expenditure and mobilize hepatic lipids — effects that tirzepatide's dual-agonist mechanism does not engage. The 2023 retatrutide Phase II data showed 24.2% mean body-weight reduction at the highest dose, consistent with the hypothesis that each additional non-overlapping receptor target unlocks incremental weight-reduction magnitude.

Tirzepatide remains the current best-in-class FDA-approved compound. If retatrutide's Phase III data holds up, tirzepatide's role shifts. It goes from category leader to category foundation: the drug that proved multi-receptor targeting works before the triple-agonist generation took over.

Frequently asked questions

What receptors does Zepbound (tirzepatide) target? Two incretin receptors: GIP and GLP-1. Tirzepatide is a single molecule engineered as a dual agonist — the GIP arm is what separates it from semaglutide-class GLP-1 monotherapy.

What is the GIP agonist mechanism of action? GIP receptor agonism potentiates glucose-dependent insulin secretion and appears to act in adipose tissue and brain regions involved in energy balance; paired with GLP-1 agonism it produced the additive glycemic and weight effects reported across the SURMOUNT program.

Why does dual agonism beat a single agonist? The synergy argument: two receptor systems converging on appetite, insulin secretion and energy expenditure produce more than either alone — the trial-by-trial case is laid out in the sections above.